{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:22:32Z","timestamp":1790803352782,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Fujian provincial medical center of hepatobiliary"},{"name":"Fujian provincial precision medicine and precision pharmacy innovation platform construction program","award":["2018-S-wp4"],"award-info":[{"award-number":["2018-S-wp4"]}]},{"name":"clinical medicine center construction program of Fuzhou, Fujian, P.R.C","award":["2018080306"],"award-info":[{"award-number":["2018080306"]}]},{"name":"key clinical specialty discipline construction program of Fujian"},{"name":"Innovation platform construction for clinical evaluation of liver and infectious disease drugs","award":["2019-S-wp6"],"award-info":[{"award-number":["2019-S-wp6"]}]},{"name":"Fujian Medical University Qihang Fund Project","award":["2017XQ1168"],"award-info":[{"award-number":["2017XQ1168"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jpba.2019.113076","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T12:33:40Z","timestamp":1577363620000},"page":"113076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS\/MS"],"prefix":"10.1016","volume":"180","author":[{"given":"Lingjie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.113076_bib0005","series-title":"Global Tuberculosis Report","author":"World Health Organisation","year":"2018"},{"key":"10.1016\/j.jpba.2019.113076_bib0010","unstructured":"WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis 2018 update, 2018, World Health Organisation, Geneva."},{"key":"10.1016\/j.jpba.2019.113076_bib0015","series-title":"WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment","year":"2019"},{"key":"10.1016\/j.jpba.2019.113076_bib0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2019.113076_bib0025","unstructured":"WHO guidelines on tuberculosis infection prevention and control 2019 update, 2019, World Health Organisation, Geneva."},{"key":"10.1016\/j.jpba.2019.113076_bib0030","series-title":"British HIV Association Guidelines for the Management of Tuberculosis in Adults Living with HIV","year":"2018"},{"key":"10.1016\/j.jpba.2019.113076_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.15583\/jpchrom.2015.020","article-title":"Application of liquid chromatography coupled with electrospray ionization tandem mass spectrometry for therapeutic drug monitoring of sedative medicine in clinical stage","volume":"36","author":"Inoue","year":"2015","journal-title":"Chromatography"},{"key":"10.1016\/j.jpba.2019.113076_bib0040","first-page":"17m12086","article-title":"Difference in duloxetine dosing strategies in smoking and nonsmoking patients: therapeutic drug monitoring uncovers the impact on drug metabolism","volume":"75","author":"Augustin","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpba.2019.113076_bib0045","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/606056","article-title":"Pharmacokinetic evaluation of Rifabutin in combination with Lopinavir-Ritonavir in patients with HIV infection and active tuberculosis","volume":"49","author":"Boulanger","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.113076_bib0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2019.113076_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dku382","article-title":"Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir","volume":"70","author":"Moultrie","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2019.113076_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography- electrospray ionization-tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.113076_bib0065","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apm.12590","article-title":"Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography\/ tandem mass spectrometry","volume":"124","author":"Prahl","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.jpba.2019.113076_bib0070","doi-asserted-by":"crossref","first-page":"061","DOI":"10.7324\/JAPS.2018.8910","article-title":"Simultaneous determination of phrazinamide, rifampicin, ethambutol, isoniazid and acetyl isoniazid in human plasma by LC-MS\/MS method","volume":"8","author":"Luyen","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.113076_bib0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tube.2017.11.012","article-title":"Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS\/MS: Application to therapeutic drug monitoring","volume":"109","author":"Gao","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jpba.2019.113076_bib0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2018.10.027","article-title":"Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry","volume":"1105","author":"Sundell","year":"2019","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.113076_bib0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chroma.2018.04.026","article-title":"Standard addition with internal standardisation as an alternative to using stable isotope labelled internal standards to correct for matrix effects- comparison and validation using liquid chromatography- tandem mass spectrometric assay of vitamin D","volume":"1553","author":"Hewavitharana","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2019.113076_bib0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jchromb.2018.11.026","article-title":"Isotope-labeled versus analog internal standard in LC-MS\/MS method for tacrolimus determination in human whole blood samples- A compensation of matrix effects","volume":"1104","author":"Bodnar-Broniarczyk","year":"2019","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.113076_bib0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2018.12.008","article-title":"Development and validation of an UPLC-MS\/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma","volume":"1105","author":"Bollen","year":"2019","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2019.113076_bib0100","series-title":"Bioanalytical Method Validation Guidance for Industry","year":"2018"},{"key":"10.1016\/j.jpba.2019.113076_bib0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00216-018-1556-y","article-title":"Reversed phase UHPLC\/ESI-MS determination of oxylipins in human plasma: a case study of female breast cancer","volume":"441","author":"Chocholouskova","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2019.113076_bib0110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4155\/bio.16.27","article-title":"Development and validation of HILIC-ESI\/MS\/MS methods for simultaneous quantitation of several antipsychotics in human plasma and blood","volume":"8","author":"Meulder","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2019.113076_bib0115","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1007\/s00216-013-7049-0","article-title":"Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma","volume":"405","author":"Zhou","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2019.113076_bib0120","unstructured":"Companion handbook to the WHO guidelines for the programmaic management of drug-resistant tuberculosis in 2014. WHO\/HTM\/TB\/2014.11, 2014, World Health Organization, Geneva."},{"key":"10.1016\/j.jpba.2019.113076_bib0125","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/rcm.2961","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography\/tandem mass spectrometry","volume":"21","author":"Song","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519317182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519317182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:01:43Z","timestamp":1760000503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519317182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":25,"alternative-id":["S0731708519317182"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113076","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.113076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113076"}}